Attached files

file filename
EX-99.1 - EX-99.1 - PATHEON INCd688504dex991.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

MARCH 10, 2014

Date of Report (Date of earliest event reported)

 

 

PATHEON INC.

(Exact name of registrant as specified in its charter)

 

 

 

Canada   000-54283   Not Applicable

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File No.)

 

(IRS Employer

Identification No.)

Patheon Pharmaceuticals Services Inc.

4721 Emperor Boulevard, Suite 200

Durham, NC 27703

(Address of Principal Executive Offices, including Zip Code)

Registrant’s telephone number, including area code: (919) 226-3200

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 8.01. Other Events.

On March 10, 2014, Patheon Inc. (the “Company”) issued a press release announcing that the Ontario Superior Court of Justice (Commercial List) has issued a final order approving the Company’s previously announced statutory plan of arrangement under the Canada Business Corporations Act pursuant to which JLL/Delta Patheon Holdings, L.P. (“Newco”), which is sponsored by an entity controlled by JLL Partners Inc. and Koninklijke DSM N.V., will indirectly acquire all of the issued and outstanding restricted voting shares of the Company. A copy of this press release is attached as Exhibit 99.1 hereto.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

99.1    Press Release, dated March 10, 2014.

 

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned thereunto duly authorized.

 

    PATHEON INC.
March 10, 2014     By:  

/s/ Stuart Grant

      Stuart Grant
      Executive Vice President, Chief Financial Officer

 

3


EXHIBIT INDEX

 

Exhibit
Number

  

Description

99.1    Press Release, dated March 10, 2014.

 

4